Examkin

Soru

Zorluk: ZorPharmacologic Interventions

An ambulatory care appointment is scheduled for a 64-year-old male patient who is being managed for chronic heart failure with reduced ejection fraction (HFrEF). Over the past three months, he has noticed a progressive decline in his exercise tolerance and now experiences shortness of breath when walking up a single flight of stairs, consistent with New York Heart Association (NYHA) class III symptoms. His current daily medication regimen comprises lisinopril 40 mg, metoprolol succinate 100 mg, and spironolactone 25 mg. In the clinic, his blood pressure measures 128/82 mmHg128/82 \text{ mmHg} and heart rate is 68/min68 \text{/min}. The physical examination is notable for mild jugular venous distention and trace bilateral lower extremity edema. A recent echocardiogram confirms a left ventricular ejection fraction of 32%32\%. Serum laboratory analysis reveals a potassium level of 4.6 mEq/L4.6 \text{ mEq/L} and an estimated glomerular filtration rate of 58 mL/min/1.73 m258 \text{ mL/min/1.73 m}^2. The treating physician plans to escalate his heart failure pharmacotherapy by replacing his current renin-angiotensin system inhibitor with sacubitril-valsartan. Which of the following is the most appropriate strategy for executing this pharmacologic transition?

  1. Discontinue lisinopril and wait at least 36 hours before administering the first dose of sacubitril-valsartanCevap
  2. B
    Discontinue lisinopril and administer the first dose of sacubitril-valsartan at the next scheduled medication time
  3. C
    Continue lisinopril at half the current dose and simultaneously initiate sacubitril-valsartan to prevent acute decompensation
  4. D
    Discontinue spironolactone, wait at least 36 hours, and then initiate sacubitril-valsartan
  5. E
    Discontinue lisinopril, wait at least 36 hours, and initiate sacubitril-valsartan along with an oral potassium supplement

Cevap

The most appropriate strategy is to discontinue the ACE inhibitor (lisinopril) and wait at least 36 hours before administering the first dose of the ARNI (sacubitril-valsartan).
The correct strategy involves discontinuing the ACE inhibitor (lisinopril) and enforcing a strict 36-hour washout period before initiating the ARNI (sacubitril-valsartan). Sacubitril is a neprilysin inhibitor. Neprilysin is an enzyme responsible for degrading several vasoactive peptides, including bradykinin. ACE inhibitors also block the degradation of bradykinin. If an ARNI is initiated while an ACE inhibitor is still active in the patient's system, the dual inhibition of bradykinin breakdown leads to a rapid and profound accumulation of bradykinin. This synergistic effect dramatically increases the risk of severe, potentially life-threatening angioedema. Therefore, clinical guidelines mandate at least a 36-hour gap between the last dose of an ACE inhibitor and the first dose of an ARNI. Notably, this washout period is not required when transitioning from an Angiotensin Receptor Blocker (ARB) to an ARNI, as ARBs do not affect bradykinin metabolism.

Adım Adım Çözüm

1
Identify the patient's current clinical status and medication regimen.
The patient has symptomatic HFrEF (NYHA class III) despite therapy with an ACE inhibitor (lisinopril), a beta-blocker, and a mineralocorticoid receptor antagonist.
Establishing the baseline helps determine the indication for escalating therapy to an Angiotensin Receptor-Neprilysin Inhibitor (ARNI).
2
Recognize the specific pharmacologic transition being planned.
The physician is replacing lisinopril with sacubitril-valsartan.
The combination of these specific drug classes introduces unique and dangerous pharmacokinetic interactions.
3
Apply the safety guidelines for initiating an ARNI in a patient currently taking an ACE inhibitor.
A mandatory 36-hour washout period must be observed between the last dose of lisinopril and the first dose of sacubitril-valsartan.
Both ACE inhibitors and neprilysin inhibitors decrease the breakdown of bradykinin. Overlapping their effects causes a synergistic accumulation of bradykinin, significantly increasing the risk of potentially fatal angioedema.

Anahtar Kavram

When transitioning a patient from an Angiotensin-Converting Enzyme (ACE) inhibitor to an Angiotensin Receptor-Neprilysin Inhibitor (ARNI), a strict 36-hour washout period is required to minimize the risk of severe angioedema.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru